Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BAL101553||Lisavanbulin||Antimicrotubule Agent 12||Lisavanbulin (BAL101553) is the prodrug of the microtubule inhibiting drug BAL27862, which may result in decreased growth and migration of tumor cells (PMID: 27540016).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||BAL101553||Phase I||Actionable||In a Phase I trial, BAL101553 treatment resulted in stable disease in 37% (7/19) of patients with advanced solid tumors (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 2530-2530; NCT02490800).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03250299||Phase I||BAL101553||Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma||Recruiting|